Synaptogenix (Synaptogenix) Total Assets : $29.40 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Synaptogenix Total Assets?

Synaptogenix's Total Assets for the quarter that ended in Mar. 2024 was $29.40 Mil.

During the past 12 months, Synaptogenix's average Total Assets Growth Rate was 51.20% per year. During the past 3 years, the average Total Assets Growth Rate was 2.00% per year.

During the past 5 years, Synaptogenix's highest 3-Year average Total Assets Growth Rate was 29.90%. The lowest was 2.00%. And the median was 15.95%.

Total Assets is connected with ROA %. Synaptogenix's annualized ROA % for the quarter that ended in Mar. 2024 was -2.74%. Total Assets is also linked to Revenue through Asset Turnover. Synaptogenix's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Synaptogenix Total Assets Historical Data

The historical data trend for Synaptogenix's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synaptogenix Total Assets Chart

Synaptogenix Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

17.90

6.75

35.53

38.61

31.11

Synaptogenix Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial														36.53	33.44	32.36	31.11	29.40

Synaptogenix Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Synaptogenix's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	25.584	+	5.529
	=	31.11

Synaptogenix's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	22.877	+	6.523
	=	29.40

Synaptogenix (NAS:SNPX) Total Assets Explanation

Total Assets is connected with ROA %.

Synaptogenix's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-0.828	/	( (31.114	+	29.399)	/ 2 )
	=	-0.828	/	30.2565
	=	-2.74 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Synaptogenix's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0	/	( (31.114	+	29.399)	/ 2 )
=	0	/	30.2565
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Synaptogenix Total Assets Related Terms

Thank you for viewing the detailed overview of Synaptogenix's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Synaptogenix (Synaptogenix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synaptogenix Inc (NAS:SNPX) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036

Website

https://www.synaptogen.com

Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.

Executives

Joshua Silverman	director	IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Robert Weinstein	officer: Chief Financial Officer	3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Bruce Bernstein	director	780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
Jonathan Schechter	director	C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
William S. Singer	director	C/O KIRKLAND & ELLIS LLP, 300 NORTH LASALLE, CHICAGO IL 60654
Daniel L. Alkon	director, officer: Chief Scientific Officer	C/O NEUROTROPE, INE., 205 EAST 42ND STREET - 20TH FLOOR, NEW YORK NY 10017
Alan J Tuchman	director, officer: Chief Executive Officer	18 SYCAMORE ROAD, MAHOPAC NY 10541
George Perry	director	C/O NEUROTROPE, INC., 205 EAST 42ND STREET, 17TH FLOOR, NEW YORK NY 10010